Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Investor Day (November 2021)
140 slides from Bristol-myers Squibb's investor day presentation, Nov 16, 2021
Slide 1: Investor Event November 16, 2021
Investor Event November 16, 2021
Slide 2: Forward Looking Statement and Non-GAAP Financial Information
Forward Looking Statement and Non-GAAP Financial Information 2 This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual
Slide 3: Today's Agenda
Today’s Agenda 3 Rupert Vessey Samit Hirawat Chris Boerner David Elkins Giovanni Caforio Strategic Overview Innovation Engine & Early Pipeline Late-Stage Pipeline Update Commercial Opportunities Financial Overview BREAK (10 min) Giovanni Caforio Closing, Q&A Conclusion, lunch reception 12:00 pm
Slide 4: Strategic Overview
Giovanni CaforioBoard Chair and Chief Executive Officer Strategic Overview
Slide 5: Our strategic foundation
A differentiated biopharma company focused on innovative medicines for patients with cancer and other serious diseases BEST OF BIOTECHBEST OF PHARMA Leading scientific innovationCollaborating at center of the biotech ecosystemLeveraging global scale and agilityDriven by the best people 5 Our strateg
Slide 6: Continued execution of biopharma strategy
Diabetes business divested, e.g. Creating our biopharma company Focusing on specialty medicines Deepening our innovation engine& long-term growth drivers BioPharma Strategyintroduced 2013 2007 2008 2009 2019 2020 2021 2017 2012 2010 2011 2014 2015 2016 2018 Continued execution of biopharma strategy
Slide 7: Deepening our innovation engine since 2019
From 11 to 22 Phase 3 & registrational expansion opportunities Deepening our innovation engine since 2019 7 Deeper pipeline Expanded research platforms Industry leading Protein Homeostasis capability Expanding Cell Therapy platforms Broader external partnership network Currently >300 From 29 to 64 P
Slide 8: Well positioned with a diverse portfolio of leading medicines
Well positioned with a diverse portfolio of leading medicines 8 Leading Products across Four Therapeutic Areas Robust Early-stage Pipeline** Across leading drug discovery platforms:Small moleculesProtein homeostasisBiologicsCell therapy **Phase I / II Assets Financial strength enabling continued inv
Slide 9: Our commitment as a sustainable organization
Our Commitment as a sustainable organization Embracing environmental stewardship 9 Experienced & diverse Board Board oversight of strategy& key enterprise risks60% female & ethnically diverse directorsShareholder rightsRegular shareholder engagementProxy access Special meeting right (15%) Environmen
Slide 10: Confidence in our ability to address future LOE exposures
Confidence in our ability to address future key LOE exposures 10 Mid to late stage Pipeline Early-Stage Pipeline Financial strength New Product Portfolio 1H Decade Multiple drivers of growth to more than offset LOE headwinds 2H Decade $25B+ NRA revenue potential 50+ assets $45 - $50B free cash flow
Slide 11: 2020-2025 revenue growth: Continuing Business offsets LOEs
($12B – $14B) +$8B – $10B +$10B – $13B 2020 Revenues LOE Brands In-Line Brands Primarily I-O & Eliquis 2025 Revenues New Product Portfolio Growth 2020-2025Low to mid-single digit revenue CAGR* 2020-2025 revenue growth:Continuing Business offsets LOEs 11 LOE Brands = Revlimid, Pomalyst, Sprycel, and
Slide 12: Opportunity for a more diversified portfolio in 2025
Revlimid, Eliquis & I-O Opportunity for a more diversified portfolio in 2025 12 Not for Product Promotional Use New Product Portfolio All Other Eliquis & I-O New Product Portfolioexpected to represent ~25% of total company revenue expected in 2025, with continued growth expectedReduced concentration
Slide 13: New Product Portfolio has significant growth potential
New Product Portfolio has significant growth potential deucravacitinib $3B+ $4B+ Note: Non-risk adjusted sales subject to positive registrational trials and health authority approval $1B+ mavacamten rela+nivo FDC Broad New Product Portfolio with $25B+non-risk adjusted revenue potential in 2029 13
Slide 14: Broad pipeline addresses diseases with significant commercial potential
Solid Tumor Onc $80B+ Lung $25B+ CRC $7B+ Breast $21B+ Prostate $10B+ Ovarian $2B+ Renal $7B+ Melanoma $7B+ GI $1B+ H&N $2B+ Liver $1B+ Immunology $75B+ RA $28B+ Psoriasis $20B+ PsA $4B+ Ank. Spond. $1B+ Lupus $1B+ Atopic Derm $4B+ UC $6B+ Crohn’s $13B+ Hematology $40B+ MM $20B+ NHL $11B+ MDS $1B+ A
Slide 15: Business Development remains a top priority
Current focus: Emerging science-based in-licensing opportunitiesSmall & mid-sized bolt-on opportunities to strengthen innovation engine & long-term growth profile Consistent criteria for sourcing external innovation Business Development remains a top priority 15 Strategically AlignedScientifically S
Slide 16: Multiple pathways to growth from 2025 to 2029
New Product Portfolio and pipeline provide multiple pathways to growth from 2025 to 2029 New product portfolio and pipeline products will continue to provide revenue replacement power, offsetting Eliquis and I-O LOEs Additional optionality from disciplined Business Development Delivery of late-stage
Slide 17: Critical 2022 & 2023 deliverables
Critical 2022 & 2023 deliverables to unlock value of New Product Portfolio Enable expansion forReblozyl through successful1L MDS COMMANDS trial 17 deucravacitinib mavacamten Deliver successful launch of mavacamten over the next year Establish deucravacitinib as oralof choice in Psoriasis Establish b
Slide 18: What we will cover with you today
What we will cover with you today 18 Provide insight to our innovation engine Rupert Vessey Samit Hirawat Chris Boerner David Elkins Review ourmid & late-stage pipeline Discuss the building blocks of growth Review our financial strength & approach to capital allocation
Slide 19: Innovation Engine & Early Pipeline
Innovation Engine & Early Pipeline Rupert Vessey,MA, BM, BCh, FRCP, DPhil President, Research & Early Development
Slide 20: R&D Strategic Foundation
R&D Strategic Foundation An innovation company developing first-in-class & best-in-class medicines addressing significant unmet need 20 External Partnerships Portfolio Execution Talent Key Enablers of Our Success Innovative R&D Platforms Digital Innovation
Slide 21: An Integrated Approach to Research and Development
An Integrated Approach to Research and Development 21 Global Drug DevelopmentMaximize innovation and productivity for late stage and LCM opportunities Research & Early DevelopmentDrive innovation and bring forward next generation assets
Slide 22: Differentiated and Diversified Portfolio
Differentiated and Diversified Portfolio Grown through Internal R&D and BD 22 Distribution of clinical pipeline (2019 to 2021) # of assets Diversifying portfolio across TAs Rich early and mid-stage pipeline Modality agnostic approach 5 2019 40 2021 4 3 86 Neuroscience Cardiovascular Hematology Fibro
Slide 23: Industry Leading Drug Discovery Platforms
Industry Leading Drug Discovery Platforms 23 Complex Biotherapeutics Small Molecule Drug Discovery Protein Homeostasis Cell Therapy Screening2.5MM Cmpds50K CelMods Hit ValidationExploratory SAR CryoEM Lead OptimizationMedchem - RadiochemML - Cheminformatics New Targets Drug Candidates Cro Network CA
Slide 24: Novel Assets from Protein Homeostasis Platform
Novel Assets Advancing from our Protein Homeostasis Platform 24 CELMoD LDD Novel Target Cereblon Target Ligase Target ? Molecular Glue Heterobifunctional Intrinsic Degrader 1 2 3 Modalities Asset Indication Phase iberdomideA/I* CELMoD MM Late Development CC-92480A/I* CELMoD MM Late Development CC-90
Slide 25: Next Generation Cell Therapies
Broad Investment in Next Generation Cell Therapies 25 Engineered TCR T Cells for Solid Tumors CAR T Armed Payload Recognizes intracellular targets Overcoming tumor microenvironment resistance Healthy donors Patients Allogeneic CAR T Cells Off the shelf alternative Enabled through strategic partnerin
Slide 26: Immune Cell Engager Molecules
Immune Cell Engager Molecules are Complementary Modalities to Cellular Therapy 26 Current Portfolio (public) Bispecific Antibodies: Direct host immune cells (T or NK) to recognize & attack tumor cells Indication Asset Disc Pre-clinical Ph1 AML CD33 NKE AML target NKE AML target NKE Lymphoma / CLL BC
Slide 27: Active External Partnerships
>85Active Collaborations 4INDs Filed 2021 9Licenses Optioned 2021 Internal R&ED Strengths are Amplified through Active External Partnerships 27 Neuroscience Immuno- Oncology & Cell Therapy Oncogenesis Tumor Micro- Environment Mechanisms of Cancer Resistance Cross-Therapeutic Informatics & Predictive
Slide 28: Rapidly Advancing Neuroscience Pipeline
Rapidly Advancing Neuroscience Pipeline Built through External Partner Network 28 By end of 2023, five assets will have completed Phase 1 and two assets will have Phase 1 ongoing Machine learning Protein Homeostasis Protein Clearance RNA Splicing Remyelination and Repair Neuroinflammation Zeposia ap
Slide 29: Strategic Equity Investments
Opportunities for Visibility and Guidance Increasing Optionality for Additional Platforms and Technologies via Strategic Equity Investments Potential 1st mover advantage for early data access and partnership opportunitiesBoard observer seats provide opportunities to provide guidance on research and
Slide 30: Integrating AI & Machine Learning into Drug Discovery
Integrating AI & Machine Learning into Drug Discovery and Development to Enable Better Decisions and Faster Execution 30 Compound OptimizationReduced cycle times |Computer assisted design Phenotypic ScreeningNovel targets | CELMoD ® MoA Biomarker DiscoveryMulti-omics analysis | Digital pathology | I
Slide 31: Phase 1 / Phase 2 Pipeline
BCMA TCE GSPT1 CELMoD(CC-90009) Phase 1 POC / initiation of registrational development Hematology Fibrosis Immunology Oncology Cardiovascular Neuroscience Phase 1 / Phase 2 Pipeline Anti-SIRPα1(CC-95251) BCMA CAR T(bb21217) BET Inhibitor1(CC-90010) BET Inhibitor (CC-95775) FXIa Inhibitor S1PR1 Modul
Slide 32: CC-99282, a novel CELMoD degrader optimized for NHL
CC-99282, a novel CELMoD Ikaros/Aiolos degrader optimized for NHL CC-99282 designed for rapid and maximal substrate degradation profileDemonstrates broad and potent cell autonomous activity (cell death) in DLBCL cell linesSignificant in vivo activity in both ABC and GCB DLBCL xenografts, with regres
Slide 33: CC-99282-NHL-001 study design and objective
CC-99282-NHL-001a: study design and objective 33 aStudy number NCT03930953; CAR, chimeric antigen receptor; FL, follicular lymphoma; MTD, maximum tolerated dose; PK, pharmacokinetics; RP2D, recommended phase 2 dose; R/R, relapsed or refractory. Key eligibility criteria (Part A)R/R DLBCL or FL≥ 2 pri
Slide 34: CC-99282: Encouraging Early Profile in NHL
CC-99282: Encouraging Early Profile in NHL Patient baseline characteristic Overall (n = 35) Age, median (range), years 66.0 (35–81) DLBCL, n (%)FL, n (%) 30 (85.7)5 (14.3) No. of prior anticancer tx, median (range) 3 (1–8) Failure of last anticancer tx, n (%) 20 (57.1) Stem cell transplant, n (%) 7
Slide 35: CC-95251: A Novel anti-SIRP-alpha Monoclonal Antibody
CC-95251: A Novel anti-SIRP-alpha Monoclonal Antibody ADCP, antibody-dependent cellular phagocytosis; FcγR, Fc gamma receptor; NHL, non-Hodgkin lymphoma; SIRPα, signal regulatory protein alpha. Abstract 2493: Interim results from the first clinical study of CC-95251, an anti-signal regulatory protei
Slide 36: CC-95251: Phase 1 study design and dose schedule
CC-95251: Phase 1 study design and dose schedule Dose escalation Dose expansion aAdministered intravenously. b375 mg/m2; cAdministered at/below the MTD. Key eligibility criteriaInclusion criteria:CD20+ R/R NHLECOG PS 0–1Disease progression on standard anticancer therapy or no approved conventional t
Slide 37: CC-95251: Encouraging Early Profile in NHL
CC-95251: Encouraging Early Profile in NHL aRelated to CC-95251; bSafety population; cIncluding a grade 5 septic shock not related to treatment; dEfficacy-evaluable population.AST, aspartate aminotransferase; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL,
Slide 38: BMS-986415: Novel IL-12 Fc
Pleiotropic effects on innate and adaptive immune cells within the TMEStriking antitumor activity in a variety of preclinical models (monotherapy and in combination) Monovalent IL-12 Fc fusion protein Extended half-life prolonged IFNg PD response, broadening therapeutic indexFirst-in-class opportuni
Slide 39: CT26: Large Tumors preclinical data
CT26: Large Tumors Preclinical mouse surrogate molecule shows extended PK prolongs PD and provides single agent efficacy 39 Prolonged and Moderate (Peripheral) IFN response mDF6006 (1 µg single dose) CT26: Checkpoint-nonresponsive Model mDF6006 (mouse surrogate of BMS-986415, 1 µg weekly IP or SQ)T
Slide 40: BMS-986415: Study status and updates
Study progress: Dose escalation ongoing, no dose limiting toxicities to date Mono escalation: Enrolling BMS-986415: Study status and updates 40 Combination escalation with nivolumab: Enrolling Biotherapeutic
Slide 41: Biological Rationale for Targeting the IL-8 Pathway
Biological Rationale for Targeting the IL-8 Pathway Primary Hypothesis (Role of IL-8 in Immunosuppressive Tumor Microenvironment):IL-8 blockade will relieve immune suppression induced by PMN-MDSC to enhanced anti-tumor immunity in combination with nivolumab 41 Bakouny, Z., Choueiri, T.K. IL-8 and ca
Slide 42: Role of IL-8 in Mediating I-O Resistance
Role of IL-8 in Mediating I-O Resistance was Validated using Phase 3 Checkpoint Inhibitor Clinical Trials 42 Schalper KA et al. Nat Med 2020;26:688-692 IL-8 promotes the trafficking of immunosuppressive PMN-MDSCs into TME (CM-017, CM-057) Reduced OS in CPI Treated Patients with elevated Serum IL-8 (
Slide 43: BMS-986253 shows Preliminary Clinical Activity in Melanoma
BMS-986253: A Novel Anti-IL-8 Monoclonal Antibody shows Preliminary Clinical Activity with Nivo in Melanoma 43 Durable stable disease and partial responses were observed in patients with melanomaPartial responses were observed in 5 of 28 patients with melanoma; all 5 patients with partial response h
Slide 44: BMS-986253: Randomized Ph2 in Post-PD(L)1 Melanoma
BMS-986253:Pursuing Formal Proof of Concept in a Randomized Ph2 in Post-PD(L)1-Treated Melanoma Patients 44 Arm A: nivo/ipi/anti-IL-8 Randomize All Comers(1:1) Arm B: nivo/ipi Stratify by serum IL-8, BRAF and LDH Patient Population:Unresectable or Metastatic Melanoma, with progression on PD(L)1 inhi
Slide 45: Innovation Engine provides opportunity for pipeline sustainability
Innovation Engine provides significant opportunity for pipeline sustainability Rich and deep pipeline across modalities and therapeutic areasIndustry leading internal discovery platforms across small molecules, complex biologics, protein homeostasis, and cell therapyStrong complementary external net
Slide 46: Late-Stage Pipeline Update
Samit HirawatChief Medical Officer,Global Drug Development Late-Stage Pipeline Update
Slide 47: Significant progress advancing the pipeline
Significant progress advancing the pipeline Cardiovascular - Oncology - Hematology - Immunology AHAmilvexianmavacamten ASHBreyanziCELMoDs Furthering development of expansion opportunities Advancing science across all key therapeutic areas Important new data at recent conferences EADVdeucravacitinib
Slide 48: Opportunity for sustained leadership in Cardiovascular
Opportunity to extend our leadership in anti-thrombotics Successful history of developing leading CV medicines Expand into cardiomyopathies Opportunity for sustained leadership in Cardiovascular 48 mavacamten milvexian Cardiovascular
Slide 49: Substantial unmet need persists in thrombotic diseases
Substantial unmet need persists in thrombotic diseases Bleeding risk currently limits usage 49 Significant opportunity for an agent with comparable or better efficacy & reduced bleeding risk over Factor Xa inhibitors Patients with high bleed risk also at higher thromboembolic risk Concerns today wit
Slide 50: Oral FXIa inhibitor mechanism of action
MOA supports opportunity to improve benefit/risk profile with an oral FXIa inhibitor 50 Extrinsic Pathway Intrinsic Pathway Tissue Factor FVIIa FVII Vesselinjury Common Pathway FXII FXIIa FIX FIXa FX FXa FII FIIa/Thrombin FXI FXIa Thrombin Feedback apixaban milvexian Cardiovascular
Slide 51: Milvexian Phase 2 trials inform Phase 3 program
Milvexian Phase 2 trials will inform optimal dose/regimen for Phase 3 program Positive trialFull data presented at AHA 2021 & in NEJM* Secondary Stroke Prevention (SSP) Study Milvexian + clopidogrel + aspirin vs placebo + clopidogrel + aspirin in patients with acute ischemic stroke or transient isch
Slide 52: Milvexian Phase 2 TKR trial design
Milvexian Phase 2 TKR trial design Milvexian vs enoxaparin*Open-label multicenter, dose-ranging study 25 mg to 400 mg total daily dose10 to 14 day exposureStudy objectives:To demonstrate effectiveness in preventing total VTE events during treatment periodTo assess the dose response of milvexian for
Slide 53: Profile of milvexian is differentiated from existing anti-thrombotics
Profile of milvexian is differentiated from existing anti-thrombotics 53 N*: based on efficacy (ITT) data set enoxaparin, mg milvexian, mg N* 40 mg QD (n=252) 25 mg QD (n=28) 50 mg QD(n = 127) 25 mg BID(n = 129) 50 mg BID(N = 124) 200 mg QD (n=123) 100 mg BID (n=134) 200 mg BID (n=131) All VTE + all
Slide 54: Scientific community recognizes important milvexian data
Scientific community recognizes important data for Milvexian, potential next generation anti-thrombotic 54 Cardiovascular
Slide 55: Milvexian Phase 2 SSP trial design
Milvexian Phase 2 SSP trial design 55 Topline data expected 1H 2022 Study objectives:Provide data on top of dual anti-platelet therapyAssess longer exposure — up to 90 day treatmentFurther insight into efficacy and bleeding profile \ 2350subjects R Arm A – placebo + 100 mg aspirin + 75 mg clopidogre
Slide 56: Multiple potential opportunities for novel antithrombotic
Multiple potential opportunities for novel antithrombotic Anti-platelets1SSPACSCAD/PAD Factor Xa1VTEAFIB Potential universe of indications Milvexian Optionality for Ph3 program pending SSP Ph2 results SSP = secondary stroke prevention; ACS = acute coronary syndrome; CAD = coronary artery disease; PA
Slide 57: Milvexian: opportunity for next generation anti-thrombotic
Opportunity to improve outcomes for patients on existing treatments Milvexian: significant opportunity for next generation anti-thrombotic Ph3 program expected to begin as early as 2H 2022 57 Similar or better efficacyBetter bleeding profile Clear benefit over enoxaparin No major bleeds observed; no
Slide 58: Hypertrophic cardiomyopathy disease profile
Hypertrophic cardiomyopathy (HCM) disease profile Significant unmet need for symptomatic HCM Thickening of the heart muscle due to:hypercontractility — impaired relaxation — hypertrophyAffects 1 in 500 people; most common genetic heart disease Symptoms include: palpitation, dizziness, breathlessness
Slide 59: Mavacamten: first-in-class medicine in oHCM
Mavacamten: a potential first-in-class medicine that addresses underlying disease in oHCM Marked improvements in cardiac function & symptoms: 65% pts improved by ≥ 1 NYHA class (vs 31% with placebo)Clinically meaningful reduction in LVOT gradients; sustained reduction in key cardiac biomarkers Posit
Slide 60: Expanding the oHCM label with VALOR-HCM
Expanding the oHCM label with VALOR-HCM 60 Primary EndpointComposite ofdecision to proceed with SRT prior to or at wk 16+ SRT guideline eligible at wk 16, but declined VALOR-HCM Study Design Patients with symptomatic oHCM, eligible for SRT*N=100 (US only) 1:1 Randomization mavacamten2.5,5,10,15 mg Q
Slide 61: Long-term MAVERICK data in nHCM
AHA 2021 (abstract #9685)Long term data demonstrate:Sustained NT-proBNP reductionImprovement in cardiac fill & function, as measured by E/e’ & LAVI No new safety signals Median (IQR) NT-proBNP over time in the total population (N = 43) Data from MAVERICK, & MAVERICK cohort of MAVA-LTE support Ph3 in
Slide 62: Mavacamten indications and pipeline opportunities
Mavacamten indications and pipeline opportunities 62 P1 P2 P3 Mavacamten has potential to make a significant impact in the CV space, starting with oHCM EXPLORER-HCM oHCM NYHA ClassII & III completed oHCM potential SRT alternative VALOR-HCM MAVERICK-HCM and MAVA-LTE nHCM EMBARK-HFpEF Precision diasto
Slide 63: Opportunity to advance leadership in Hematology
Advance broad early pipeline Leverage leading expertise in hematology Expand key new medicines Opportunity to advance leadership in Hematology 63 Hematology
Slide 64: Upcoming ASH data support hematology pipeline progress
CC-92480CC-92480+bort+dex in 4L+ MM patients (presentation #2731)Differentiated potency supported by encouraging clinical combination data Upcoming ASH data support important progress advancing hematology pipeline 1st cell therapy to demonstrate benefit over SOC 2L LBCL data (TRANSFORM) (presentatio
Slide 65: Breyanzi TRANSFORM data
Breyanzi TRANSFORM data: demonstrates further potential of Cell Therapy treatments 65 Supports Breyanzi as potential new SOC for 2L treatment in R/R LBCL mEFS = 10.1 (95% CI, 6.1–NR); HR=0.349;P < 0.0001 Primary endpoint: mEFS ORR = 86% (95% CI, 77%–92.3%)P < 0.0001 Secondary endpoint: ORR First the
Slide 66: Continuing to expand Breyanzi
Continuing to expand Breyanzi Best-in-class CD19*Strong efficacy demonstrated in 2L and 3L+ LBCLDifferentiated side effect profile, incl. low rates of CRS & NE 66 Registrational program & data availability TRANSFORM 2L TE (Breyanzi vs SOC) TRANSCEND-CLL-004 Phase I Phase II Pivotal PILOT 2L TNE (sin
Slide 67: CELMoDs could replace the current foundation of care
CELMoDs could replace the current foundation of care 67 1L 2L 3L 4L Revlimid today Pomalyst today Replace Revlimid as foundation of frontline multiple myeloma treatment Iberdomide vision Replace Pomalyst as foundation of treatment in relapsed refractory multiple myeloma (RRMM) CC-92480 vision Succes
Slide 68: Iberdomide: Phase 1b/2a study design
Iberdomide: CC-220-MM-001: Phase 1b/2a study design 68 RRMM, prior len or pomPrior proteasome inhibitorDocumented PD during or within 60 days of last anti-myeloma therapy Cohort D:iber (1.6mg qd, RP2D) + dex Cohort E: iber + dara + dex(iber: 1.0mg qd-1.6mg qd) Study endpoints:Primary: to determine M
Slide 69: Iberdomide + dex: profile supports earlier lines
Note: all data shown on slide per ASH 2021 abstract; data to be presented Cohort D Grade 3-4 TEAEs: neutropenia 44.9% anemia 28% thrombocytopenia 21.5% leukopenia 20.6% GI disorders 5.6% fatigue 2.8% rash 1.9% dose interruptions due to TEAEs 52.3% dose reductions due to TEAEs 18.7% discontinuances d
Slide 70: Iberdomide triplet combinations
Iberdomide triplet combinations: Promising responses & manageable safety profile in heavily pretreated patients 70 ORRa 45.9% ORRa 56% ORRa 50.0% aPR or better; bIncludes neutropenic sepsis. Lonial S, et al. Oral presentation at EHA 2021; abstract S187 Cohort E Cohort F Cohort G Favorable safety pro
Slide 71: Iberdomide: plans to develop as new backbone in early line MM
EXCALIBER NDMM (TNE):Iber+bort+dex / iber+dara+dex, vs. RVd Iberdomide: Plans to develop as a new backbone in early line MM 71 2L+ Post transplant maintenance:Iber vs. Revlimid EXCALIBER RRMM:Iber+dara+dex vs. dara+bort+dex NDMM NDMM 2023 2023 Expected initiation timing 1H 2022 Hematology
Slide 72: CC-92480-MM-002: study design and objective
CC-92480-MM-002: study design and objective 72 Key eligibility criteria (Cohort A)RRMM; 2–4 prior regimens including LENDisease progression during or after their last antimyeloma therapy Study endpointsPrimary: to determine MTD/RP2D and to assess safety and preliminary efficacySecondary: to evaluate
Slide 73: Differentiated potency for CC-92480
Differentiated potency for CC-92480 supported by encouraging clinical combination data 73 CC-92480 & dex: Scan from expansion phase Patient with EMP, extramedullary plasmacytoma The median duration of response was 10.4 (5.5–not reached) months Median time to response was 0.95 (0.7–3.3) months aPR or
Slide 74: CC-92480: Potential opportunity to replace Pomalyst
CC-92480: Potential opportunity to replace Pomalyst for 2L+ MM patients 74 4L+ CC-92480 + dex Status: Ph2 ongoing to inform Ph3 program CC-92480+Vd vs PVd; CC-92480+Kd vs Kd 2L+ Expected to initiate registrational trials in 2023 CC-92480 + dex + bort / cfz / dara / isa / elo Ph2 ongoing to inform Ph
Slide 75: Advancing our BCMA portfolio
Advancing our BCMA portfolio 75 1 In partnership with Dragonfly2 In partnership with Sutro3 In partnership with 2seventy bio Immune Cell Engagers Antibody Drug Conjugate T-Cell Engager CC-93269Encouraging early IV dataProgram now focused on subcutaneous formulationto maintain efficacy & reduce CRSNK
Slide 76: Important progress advancing our Multiple Myeloma strategy
Important progress advancing our Multiple Myeloma strategy 76 STRATEGIC OBJECTIVES Potential to improve upon IMiD agents and create new backbone Establish BCMA as theoptimal MM target Redefine SoC acrosslines of therapy BCMA targeting agents CELMoD agents Strategic objectives Combinations Continued
Slide 77: Robust Hematology Pipeline
Robust Hematology Pipeline 77 Phase 1 Phase 2 Marketed iberdomide BCMA TCE CD33 NKE BCMA NKE BCMA CAR T(bb21217) ROR1 CAR T A/I CELMoD(CC-92480) CK1α CELMoD BCMA NEX T CD19 NEX T BET Inhibitor(BMS-986158) A/I CELMoD(CC-99282) GSPT1 CELMoD(CC-90009) Anti-SIRPα1 Pivotal Expansion opportunities: Rebloz
Slide 78: Leverage expertise to broaden & diversify in Oncology
Diversify beyond I-O with differentiated platforms & novel MOAs Continue to expand Opdivo / Yervoy Extend I-O leadership through the next-generation of assets Leverage expertise to broaden & diversify in Oncology 78 Oncology rela+nivo FDC bempeg MORAb-202 ADC
Slide 79: Continuing to grow Opdivo / Dual I-O
Continuing to grow Opdivo / Dual I-O 1 as part of collaboration with NEKTAR 2 potential applicability in both metastatic & early stage disease Metastatic Setting Tumor/Trial Status Tumor/Trial Status 1L MelanomaCA045-001Opdivo + bempeg1 vs Opdivo 1H 2022 Readout Prostate (mCRPC)CM-7DXOpdivo + Chemo
Slide 80: Expanding Opdivo use in early-stage lung cancer
a Per BIPR; pCR: 0% residual viable tumor cells in both primary tumor (lung) and sampled lymph nodes; b ITT principle: patients who did not undergo surgery counted as non-responders for primary analysis; c Calculated by stratified Cochran–Mantel–Haenszel method; d pCR rates 95% CI: NIVO + chemo, 18.
Slide 81: Next novel I-O combination: relatlimab + nivolumab
Next novel I-O combination: relatlimab + nivolumab 81 LAG-3 and PD-1 are distinct immune checkpoints, often co-expressed on tumor-infiltrating lymphocytes, and contribute to tumor-mediated T-cell exhaustion1,2In preclinical models, LAG-3 and PD-1 blockade demonstrated synergistic antitumor activity1
Slide 82: Rela + Nivo FDC: broad expansion program
Rela + Nivo FDC: broad expansion program 82 Melanoma NSCLC 1L – Relativity -047 Adjuvant (Stage 3/4): CA 224-098 rela+nivo vs nivo 1L: CA224 -095 rela+nivo+chemo vs pembro+chemo HCC 1L: CA224 -106 rela+nivo+bev vs nivo+bev 2L IO naïve: CA224 -073rela+nivo vs nivo 1L: CA224 -104 rela+nivo+chemo vs ni
Slide 83: Bempeg: additional next generation I-O opportunity
Pegylated IL-2 partnered with NEKTAR Therapeutics Bempeg: additional next generation I-O opportunity 83 Melanoma Renal Adjuvant Mel: PIVOT-12nivo+bempeg vs. nivo2Readout: 2025 Bladder Peri-Surgical MIBC: CA045-009 nivo+bempeg vs. nivo vs. SOC1Readout: 2023 1L cis-ineligible: PIVOT-10nivo+bempeg2Read
Slide 84: MORAb-202 is a novel folate receptor alpha ADC
MORAb-202 is a novel folate receptor alpha ADC 84 Differentiated payload (eribulin) Demonstrated single agent clinical activity across multiple tumor types In partnership with EisaiTumors of interest include ovarian, NSQ NSCLC, breast, endometrialHigh addressable population based on range of FR expr
Slide 85: Robust Oncology Pipeline
Phase 1 Phase 2 Phase 3 Marketed Robust Oncology Pipeline Anti-Fucosyl GM1 Anti-OX40 STING Agonist Anti-NKG2A motolimod Anti-TIM3 Anti-CTLA-4 NF Anti-CCR8 Anti-CTLA-4 Probody AR LDD CD3xPSCA(GEMoaB)2 Anti-IL-8 Anti-TIGIT relatlimab1 bempegal-desleukin linrodostat TGFβ Inhibitor LSD1 Inhibitor1 BET I
Slide 86: Multiple promising early assets across immune-mediated diseases
Multiple promising early assets across immune-mediated diseases Foundation in Immunology today Expansion opportunities underway Building an exciting pipeline in Immunology Rheumatology / Gastroenterology / Dermatology (CD) 86 (MS,UC) Immunology deucravacitinib cendakimab
Slide 87: Deucravacitinib: first-in-class selective TYK2 inhibitor
DeucravacitinibA first-in-class selective TYK2 inhibitor in moderate-to-severe psoriasis, with proven differentiation Deucravacitinib has potential to become new oral standard of care in psoriasis 87 Clinically meaningful efficacySuperior to apremilast, comparable to1st generation biologicsDurable r
Slide 88: Long-term data support differentiated efficacy profile
Missing data were imputed using nonresponder imputation.sPGA response defined as a score of 0 or 1, with ≥2-point improvement from baseline.PASI, Psoriasis Area and Severity Index; PASI 75, ≥75% reduction from baseline in PASI; PASI 90, ≥90% reduction from baseline in PASI; PASI 100, 100% reduction
Slide 89: Labels for approved JAK inhibitors reflect JAK lab signature
Labels for approved JAK 1,2,3 inhibitors reflect known JAK lab signature tofacitinib upadacitinib baricitinib MOA(in vitro JAK 1-3 selectivity) JAK 1, 2, 3 JAK 1, 2 Anemia (Hemoglobin) Do not initiate in pts with< 9 g/dLInterrupt in pts with < 8 g/dL or decrease of >2 g/dLMonitoring for potential ch
Slide 90: No JAK-like signature across lab results
Results through one year confirm no clinically meaningfulchanges from baseline and no JAK-like signature across lab results Graphs display as observed data for patients randomized to deucravacitinib at baseline in PSO-1 who continued treatment until Week 52.LLN, lower limit of normal; QD, once daily
Slide 91: Deucravacitinib Phase 3 study in Psoriatic Arthritis
Deucravacitinib Ph 3 study ongoing in Psoriatic Arthritis 91 Data from Phase 2 Primary endpoints:ACR20Secondary endpoints included:DAS28-CRPHAD-DI (disability index questionnaire)PASI-75 Phase 3 Program (moderately to severely-active PsA) Deucravacitinib in Psoriatic Arthritis (PsA) Deucravacitinib
Slide 92: Deucravacitinib in two inflammatory bowel diseases
Opportunity to evaluate the potential for deucravacitnib in two important inflammatory bowel diseases Ulcerative ColitisInitial Ph2 study in moderate-to-severe UC (LATTICE-UC) did not meet primary & key secondary endpointsSecond Ph2 trial (IM-024-127, below) to assess potential at higher dose, with
Slide 93: Additional expansion opportunities for deucravacitinib
Additional expansion opportunities for deucravacitinib 93 Psoriatic Arthritis Registrational Ongoing Ph 2 POC Psoriasis Systemic Lupus Erythematosus Crohn’s Disease Ulcerative Colitis Filed in U.S. & EU IM-011-127 Phase 2expected 2022/2023 Phase 3 enrolling; Readout: 2024 Readout: Early 2022 Readout
Slide 94: Zeposia in IBD: UC and potential Crohn's expansion
Established IBD presence with Zeposia UC,with potential expansion to Crohn’s Disease 94 Primary endpoints:Induction studies: Week 12 clinical remissionMaintenance study: Co primary @ Week 52 clinical remission and endoscopic response Crohn’s Ph 3 Study Design (YELLOWSTONE) Zeposia in IBD Zeposia Pla
Slide 95: EoE overview and cendakimab
EoE Overview:High unmet need, currently no approved therapiesLife altering disease for ~700k pts (combined U.S./EU5) EoE: POC established with Ph2 data Continuing to build with cendakimab High affinity IL-13 neutralizing antibody 95 IL-13Ra1 IL-13Ra2 Fibrosis & Remodeling IL13 IL13 Inflammation X X
Slide 96: Emerging Immunology Pipeline
Emerging Immunology Pipeline 96 Phase 1 Phase 2 Phase 3 Marketed Imm. Tolerance (Anokion)1 MK2 inhibitor branebrutinib IL2-CD25 iberdomide S1PR1 Modulator deucravacitinib cendakimab Anti-CD40 afimetoran (TLR 7/8 inhibitor) TYK2 inhibitor 1 BMS has an exclusive option to license and/or option to acqu
Slide 97: Advancing the pipeline across all therapeutic areas
Advancing the pipeline across all therapeutic areas CardiovascularMavacamten EXPLORER LTE presentationMilvexian TKR Ph 2 positive data OncologyAdvancement of Opdivo expansion programsRela+Nivo FDC PDUFA dateMarch 19, 2022 HematologyCELMoDs new combination dataBreyanzi TRANSFORM data Immunologydeucra
Slide 98: Multiple exciting milestones ahead
deucravacitinib PsO EU approval PsA Ph3CD & DLE Ph2 (POC)2nd Ph2 in UC IM011-127 PsA Ph3 CD & DLE Ph2 (POC) cendakimab EoE Ph3 Zeposia CD Ph3 Induction/Maintenance mavacamten HFpEF Ph2 EMBARK (POC) Opdivo (+/- Yervoy) Metastatic: 1L ESCC (CM-648) approvalEarly-stage: Neo-adj lung EFS (CM-816) approv
Slide 99: Program will reconvene following a short break
Program will reconvene following a short break (10 min)
Slide 100: Commercial Opportunities
Chris BoernerChief Commercialization Officer Commercial Opportunities
Slide 101: Building blocks of our Continuing Business
Building blocks of our Continuing Business deucravacitinib $3B+ $4B+ Key in-line growth drivers Key pipeline $1B+ mavacamten rela+nivo FDC Broad New Product Portfolio with significant non-risk adjusted revenue* potential in 2029 + Expansion opportunities across multiple assets milvexian BCMA TCE cen
Slide 102: In-line growth drivers contribute $8B to $10B growth
In-line growth drivers contribute $8B to $10B growth from 2020-2025 $8.7B 2020 Combined SalesContinued growth opportunity: 102 Drive leadershipin NOAC class ExpandNOAC class Increasetreated population A standard of care across 11 tumors $9.2B 2020 SalesContinued growth opportunity: Maintain leadersh
Slide 103: Ability to extend leadership in thrombotic diseases with milvexian
Milvexian Ability to extend leadership in thrombotic diseases with milvexian 103 Building upon history of successful partnerships in CV Peak global sales:$7.1B (2011) FY global sales:$9.2B (2020) Potential to widely span arterial & venous diseasesOpportunity to launch prior to Eliquis LOE in 20281 P
Slide 104: Positive feedback from cardiologists on mavacamten
Mavacamten is the first therapeutic candidate to target the heart muscle proteins… with the intent of correcting the abnormal function of the heart.” Positive feedback from cardiologists on mavacamten 104 Physicians recognize a need for options that address underlying disease vs. treat symptomsDesir
Slide 105: $4B+ 2029 NRA sales potential for mavacamten
$4B+ 2029 NRA sales potential for mavacamten 105 HCM patient population 1.3M patients1 Significant HCM pts with obstructive disease (requiring chronic treatment) 60-70% >$4B Opportunity to drive significant penetration with a strong profile based on EXPLORER + nHCM & additional expansion indications
Slide 106: Deucravacitinib's profile resonates with dermatologists
Deucravacitinib’s differentiated profile in psoriasis resonates with dermatologists 106 Based on interview & survey responses for POETYK data in psoriasis: MOARecognized as novel EfficacyViewed as compellingComparable to first-generation biologicsSuperior to current oral therapy SafetyTolerable, wit
Slide 107: Deucravacitinib positioned to become oral of choice in psoriasis
Topicals* Current Orals** ~1.9M Patients ~0.4M Patients Source: Decision Resources Group PsO Report; Symphony Health Claims data 2020 (US); BMS Internal Estimates Note: Numbers indicate patients on any prescribed treatment (systemic, topical, advanced) in G7 countries *Includes patients treated with
Slide 108: Significant sales potential in moderate-to-severe psoriasis
Significant sales potential in moderate-to-severe psoriasis 108 Large patient population ~3M patients1 Opportunity to expand systemic oral market By ~10% e.g., through earlier discontinuation of topicals Opportunity to establish oral-of-choice Biologic-like efficacy superior to existing oral SoCFavo
Slide 109: $4B+ 2029 NRA opportunity with deucravacitinib
109 $4B+ 2029 NRA opportunity to treat patients with immune-mediated diseases with deucravacitinib Opportunity to become oral of choice in mod-to-severe PsO Broaden into Rheumatology, GI & beyond >$4B NRA salesin 2029 +2M Pts IBD Mod-Severe(UC/CD) +1M Pts +2M Pts Psoriatic Arthritis ~3M Pts Psoriasi
Slide 110: Reblozyl has $4B+ non risk adjusted sales potential
Reblozyl has $4B+ non risk adjusted sales potential in 2029 Currently approved inTransfusion dependent beta-thal2L RS+ MDS 110 Potential expansion opportunities:1L MDS with COMMANDSMF and others Opportunity to drive growthin current indications:Increase share in ESA refractory populationIncrease adh
Slide 111: Opportunity to establish Reblozyl in 2L RS+ MDS
Important opportunity to establish Reblozyl in 2L RS+ MDS 111 Patient population ~8K patients1 Demonstrated repeated periods of transfusion independence ~50% of patients may not respond to ESAs2; there is potential to treat appropriate patients sooner ESA retreatment Increase adherence Drive adoptio
Slide 112: $4B+ non risk adjusted opportunity with Reblozyl
112 $4B+ non risk adjusted opportunity with Reblozyl in 2029 Expansion into 1L MDS Establishment of novel MoA Entry into adjacent disease areas Notes regarding patient #s: MF & MDS represent combined U.S./EU5 estimates; beta-thal represents U.S. only; noted for each indication in launch year for lea
Slide 113: $3B+ Non risk adjusted sales potential for Zeposia
$3B+ Non risk adjusted sales potential in 2029 113 Opportunity to become the oral SOC in UC:Focused on increasing trialists & experienceStep wise approach to growing & broadening access over time Potential expansion opportunity:Further build presence in IBD with Crohn’s disease NRA: Non-Risk Adjuste
Slide 114: Significant expansion opportunities for Zeposia in UC
Significant expansion opportunities for Zeposia in UC 114 Large patient population ~1.1M patients1 Expand oral market Drive share of oral market Establish a new oral SOC, as first S1P modulator with strong profile: Biologic-like efficacy with favorable safety & tolerability profileNo black box warni
Slide 115: Establish Zeposia as the oral standard of care in UC
Establish Zeposia as the oral standard of care in UC 115 2021 2022 2023 Establish awareness and acceptance of new MOAEstablish breadth & depth of trialists with differentiated oral risk/benefit profile Elevate patient on-boarding capabilities (e.g., patient services) Broaden accessAccelerate share u
Slide 116: $3B+ NRA opportunity to expand Zeposia into Crohn's
Ongoing expansion into UC Foundation in MS $3B+ NRA opportunity to expand Zeposia into Crohn’s Disease over time 116 Broaden into CD +0.9M Pts +1.1M Pts Crohn’s disease (Moderate-to-Severe) Ulcerative Colitis (Moderate-to-Severe) Multiple Sclerosis >$3B NRA salesin 2029 0.9M Pts Note: Patient #s rep
Slide 117: Well positioned to unlock the full potential of Cell Therapy
Well positioned to unlock the full potential of Cell Therapy 117 Leading oncology company with a track record of delivering Financial flexibility to invest in current products and next generation technologies Scale & Experience to realize potential Favorable Market Dynamics Strong demand & physician
Slide 118: Breyanzi opportunity to grow into new indications
Breyanzi has opportunity to grow into new indications & move up in treatment paradigm Expand into earlier lines Enter DLBCL Broaden into other indications >$3B NRA salesin 2029 118 ~18K Pts +22K Pts +13K Ptsc +19K Pts 2L CLL 3L+ CLL 2L+ LBCL 3L+ LBCL 3L+ iNHL +22K Pts Note: Patient #s represent comb
Slide 119: $4B+ NRA opportunity with Rela+Nivo FDC
$4B+ NRA opportunity with Rela+Nivo FDC, beginning in 2022 with metastatic melanoma 119 Source: Patient Epi from Decision Resources Group; 1 US 2021 patient estimates; includes 1L treated patients & early-stage treatable patients 2 1L Mel US treated patients ~10K, about one-third with IO monos; 3 Ea
Slide 120: Multiple additional opportunities across therapeutic areas
Multiple additional opportunities across therapeutic areas Key pipeline $1B+ NRA sales in 2029 + additional expansion opportunities across multiple assets BCMA TCE cendakimab bempeg iberdomide MORAb-202 CC-92480 milvexian Cardiovascular Immunology Oncology Hematology 120 NRA: Non-Risk Adjusted Sales
Slide 121: Financial Overview
David ElkinsChief Financial Officer Financial Overview
Slide 122: Confidence in our future
Confidence in our future 122 Strong innovation engine with deep scientific expertise to replenish the portfolioIndustry leading commercial capabilities to maximize growth by reaching more patients with unmet medical needs Strong execution provides confidence to deliver the full potential of our comm
Slide 123: Key milestones
Opdivo (+/- Yervoy) U.S./EU expected approvals:1L RCC (9ER) , 1L GC (649, O+Chemo), adj Eso (577) adj MIBC (274) 1L Esophageal (CM-648) Opdivo return to annual growth Relatlimab 1L Melanoma w/ Opdivo Ph3 Breyanzi 3L+ DLBCL U.S. / EU approval3 2L TE and TNE DLBCL 3L+ CLL3 Abecma 4L+ MM U.S.1 / EU app
Slide 124: Strong execution reinforces our confidence in financial targets
Strong execution reinforces our confidence in our financial targets 124 Strong Financial Foundation and Portfolio Positioned for Growth Operating Margins in low to mid-40s**~$3B of Synergies by end of 2022$45 – 50B of Free Cash Flow from 2021-2023 Low double-digit Revenue CAGR for Continuing Busines
Slide 125: Continued In-Line performance and New Product Portfolio offset near-term LOEs
Continued In-Line performance and New Product Portfolio more than offsets impact from near-term LOEs LOE Brands = Revlimid, Pomalyst, Sprycel, and Abraxane *At constant exchange rates – Non-GAAP. There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information
Slide 126: New Product Portfolio to deliver $10B-$13B risk-adjusted revenue in 2025
We expect New Product Portfolio to deliver $10B-$13B of risk-adjusted revenue in 2025 126 AbecmaOnuregInrebicrela+nivo FDC Significantly de-risked portfolio: 9 new products: 6 approved, 3 filedIncreased confidence in expansion opportunitiesZeposia launch in UCBreyanzi 2L+ LBCL deucravacitinib PsA Ph
Slide 127: Path to maintaining Operating Margins
Path to maintaining Operating Margins 127 *Non-GAAP - There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information Low to mid-single digit Total Company Revenue CAGR from 2020 - 2025 Gross Margin decline tempered by growth in high-margin launch brands and
Slide 128: Strong cash flow provides financial flexibility
Strong cash flow provides for tremendous financial flexibility 128 $45B - $50Bin free cash flow 2021-2023 *Future dividend payouts subject to board authorization Prioritizing Business Development to replenish and diversify the portfolio to drive long-term growth Strengthening the Balance Sheet to en
Slide 129: Business Development remains a top priority
Business Development remains a top priority to complement the portfolio for long-term growth 129 Deals over the last 18 months A further diversified pipeline Oncology Hematology Immunology Cardiovascular Neurology Financial Discipline Significant capacity for business development – strong rating & F
Slide 130: Well positioned for future growth
Well positioned for future growth 130 Business continues to execute well against our financial and pipeline commitmentsStrong innovation engine for continued growth into the second half of the decadeConfident in our ability to address future LOEs Financial strength and flexibility to further strengt
Slide 131: Giovanni Caforio, Board Chair and Chief Executive Officer
Giovanni CaforioBoard Chair and Chief Executive Officer
Slide 132: Franchise durability and growth across four key therapeutic areas
Cardiovascular Opportunity for franchise durability and growth across all four key therapeutic areas Oncology Hematology Immunology 132 New Products Robust early-stage pipeline with 50+ assets in development deucravacitinib* rela+nivo FDC* bempeg iberdomide milvexian cendakimab Inline Brands Next Wa
Slide 133: Multiple exciting milestones ahead
deucravacitinib PsO EU approval PsA Ph3CD & DLE Ph2 (POC)2nd Ph2 in UC IM011-127 PsA Ph3 CD & DLE Ph2 (POC) cendakimab EoE Ph3 Zeposia CD Ph3 Induction/Maintenance mavacamten HFpEF Ph2 EMBARK (POC) Opdivo (+/- Yervoy) Metastatic: 1L ESCC (CM-648) approvalEarly-stage: Neo-adj lung EFS (CM-816) approv
Slide 134: Multiple pathways to growth from 2025 to 2029
New Product Portfolio and pipeline provide multiple pathways to growth from 2025 to 2029 New product portfolio and pipeline products will continue to provide revenue replacement power, offsetting Eliquis and I-O LOEs Additional optionality from disciplined Business Development Delivery of late-stage
Slide 135: Well positioned for the near-term and long-term
Well positioned for the near-term and long-term 135 Confident in our ability to navigate upcoming LOEs Strong position to grow and renew our business Strong cash flow and balance sheet strength support ability to execute disciplined business development Significant growth potential from new product
Slide 136: Investor Meeting Q&A
Investor Meeting Q&A 136 Giovanni CaforioBoard Chair andChief Executive Officer Chris BoernerChief Commercialization Officer David ElkinsChief Financial Officer Samit HirawatChief Medical Officer,Global Drug Development Rupert VesseyPresident, Research & Early Development
Slide 137: (lh Bristol Myers Squibb”
(lh Bristol Myers Squibb”
Slide 138: Appendix
Appendix (lh Bristol Myers Squibb”
Slide 139: Early pipeline by phase, data as of November 16, 2021
Hematology Fibrosis HSP47 LPA1 Antagonist Immunology Oncology Data as of November 16, 2021 Anti-Fucosyl GM1 Anti-OX40 TIGIT Bispecific Anti-NKG2A Anti-SIRPα1 AR LDD Anti-CTLA-4 NF Anti-CCR8 Anti-CTLA-4 Probody BCMA TCE CD3xPSCA(GEMoaB)2 IL-12 Fc Anti-IL-8 Anti-TIGIT BET Inhibitor(BMS-986158) CD19 NE
Slide 140: Abbreviations
140 Abbreviations ACC American College of Cardiology DLBCL Diffuse Large B-Cell Lymphoma MM Multiple Myeloma RR Relapsed Refractory ACR American College of Rheumatology DLE Discoid Lupus Erythematosus MR Minimal Response RS Ring Sideroblasts ACS Acute Coronary Syndrome EADV European Academy of Derma